SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olsson Anna)
 

Sökning: WFRF:(Olsson Anna) > (2005-2009) > Negative effect of ...

  • Grövdal, MichaelGrövdal, M., Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden (författare)

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome

  • Artikel/kapitelEngelska2007

Förlag, utgivningsår, omfång ...

  • 2007
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-124898
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-124898URI
  • https://doi.org/10.1158/1078-0432.CCR-07-1193DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:116291397URI
  • https://lup.lub.lu.se/record/966355URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47510URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Promoter hypermethylation of, for example, tumor-suppressor genes, is considered to be an important step in cancerogenesis and a negative risk factor for survival in patients with myelodysplastic syndromes (MDS); however, its role for response to therapy has not been determined. This study was designed to assess the effect of methylation status on the outcome of conventional induction chemotherapy. EXPERIMENTAL DESIGN: Sixty patients with high-risk MDS or acute myeloid leukemia following MDS were treated with standard doses of daunorubicin and 1-beta-d-arabinofuranosylcytosine. Standard prognostic variables and methylation status of the P15(ink4b) (P15), E-cadherin (CDH), and hypermethylated in cancer 1 (HIC) genes were analyzed before treatment. RESULTS: Forty percent of the patients achieved complete remission (CR). CR rate was lower in patients with high WBC counts (P = 0.03) and high CD34 expression on bone marrow cells (P = 0.02). Whereas P15 status alone was not significantly associated with CR rate (P = 0.25), no patient with hypermethylation of all three genes achieved CR (P = 0.03). Moreover, patients with CDH methylation showed a significantly lower CR rate (P = 0.008), and CDH methylation retained its prognostic value also in the multivariate analysis. Hypermethylation was associated with increased CD34 expression, but not with other known predictive factors for response, such as cytogenetic profile. CONCLUSIONS: We show for the first time a significant effect of methylation status on the outcome of conventional chemotherapy in high-risk MDS and acute myelogenous leukemia following MDS. Provided confirmed in an independent study, our results should be used as a basis for therapeutic decision-making in this patient group.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Khan, RasheedDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden (författare)
  • Aggerholm, AnniKarolinska Institutet,Department of Haematology, Aarhus University Hospital, Aarhus, Denmark,Department of Haematology, Sahlgrenska University Hospital, Göteborg, Sweden,Department of Pathology, Radiumhemmet, Karolinska University Hospital, Solna, Stockholm, Sweden (författare)
  • Antunovic, PetarLinköpings universitet,Hälsouniversitetet,Institutionen för biomedicin och kirurgi(Swepub:liu)petan27 (författare)
  • Astermark, JanLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Department for Haematology and Coagulation Disorders, Malmö University Hospital, Malmö, Sweden(Swepub:lu)medf-jas (författare)
  • Bernell, PerDivision of Haematology, Department of Medicine, Karolinska University Hospital, Solna, Stockholm, Sweden (författare)
  • Engström, Lena-MariaEngström, L.-M., Medical Clinic, Department of Haematology, University Hospital of Norrland, Umeå, Sweden (författare)
  • Kjeldsen, LarsDepartment of Haematology, Rigshospitalet, Copenhagen, Denmark (författare)
  • Linder, OlleDepartment of Medicine, Örebro University Hospital, Örebro, Sweden (författare)
  • Nilsson, LarsLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Haematopoietic Stem Cell Laboratory, Department of Haematology, Lund University Hospital, Lund, Sweden(Swepub:lu)med-lni (författare)
  • Olsson, Anna (författare)
  • Wallvik, JonasDivision of Haematology, Department of Medicine, Sundsvall Hospital, Sundsvall, Sweden (författare)
  • Tangen, Jon MagnusDepartment of Haematology, Ullevål University Hospital, Oslo, Norway (författare)
  • Öberg, GunnarUppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar,Öberg, G., Department of Haematology, Uppsala Academic Hospital, Uppsala, Sweden (författare)
  • Jacobsen, Sten EirikHaematopoietic Stem Cell Laboratory, Department of Haematology, Lund University Hospital, Lund, Sweden (författare)
  • Hokland, PeterDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark (författare)
  • Porwit, Anna (författare)
  • Hellström-Lindberg, EvaKarolinska Institutet,Hellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Huddinge, SE-14186 Stockholm, Sweden (författare)
  • Engstroem, LV (författare)
  • Grövdal, M., Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, SwedenDepartment of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical Cancer Research13:23, s. 7107-71121078-04321557-3265

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy